Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[211At]BC8-B10
- Development stage
- Phase 2
- Lead developer
- Fred Hutchinson Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[211At]BC8-B10 is a radioimmunoconjugate consisting of a murine IgG1 anti-CD45 monoclonal antibody (BC8) conjugated via lysine side groups to a decaborate (B10) moiety and radiolabeled with astatine-211, an alpha particle-emitting radionuclide. The resulting agent specifically targets CD45-positive cells, such as malignant hematopoietic cells, delivering targeted alpha radiation to induce cytotoxicity. It is primarily being investigated as a conditioning regimen prior to donor stem cell transplantation in patients with high-risk or relapsed/refractory acute leukemia or myelodysplastic syndrome. Developed at Fred Hutchinson Cancer Center with NCI support, it is currently in phase I/II clinical evaluation[1][2][3][4][5][6][8][9].
- Other names
- astatine-211-labeled BC8-B10astatine211-labeled BC8-B10astatine 211-labeled BC8-B10At-211-BC8-B10At211-BC8-B10At 211-BC8-B10
02
Targets
PTPRC (Receptor-type tyrosine-protein phosphatase C)
Beyond the preview
Go deeper on [211At]BC8-B10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [211At]BC8-B10.